The Use of Selective Inhibitors of Inducible Nitric Oxide Synthase in Septic Shock

Sepsis

Volumn 1, Issue 2, 1998, Pages 123-129

  Thiemermann, Christoph ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000280038     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009780509335     Document Type: Article

References (54)

1. Thiemermann C, Vane JR. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat. Eur J Pharmacol 1990;182:591-5.
2. G-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990;172:1132-8.
3. G-methyl-L-arginine inhibits tumour necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-32.
4. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC. Loss of vascular responsiveness induced by endotoxin involves the L-arginine pathway. Am J Physiol 1990;259:H1038-43.
5. Rees DD, Cellek, S, Palmer RMJ, Moncada S. Dexamethasone prevents the induction of nitric oxide synthase and the associated effects on the vascular tone: an insight into endotoxic shock. Biochem Biophys Res Commun 1990;173: 541-47.
6. G-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. J Leuk Biol 1990;48:565-569.
7. Thiemermann C. The role of L-arginine:nitric oxide pathway in circulatory shock. Adv Pharmacol 1994;28:45-79.
8. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. Horizon 1995;1:2-32.
9. Rees DD. Role of nitric oxide in the vascular dysfunction in septic shock. Biochem Soc Trans 1995;23:1025-9.
10. Wu CC, Ruetten H, Thiemermann C. Comparison of the effects of aminoguanidine and NG-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxemia in the rat. Eur J Pharmacol 1996;300:99-104.
11. Morris SM, Billiar TR. New insights into the regulation of inducible nitric oxide synthase. Am J Physiol 1994;266: E829-39.
12. Szabo C, Thiemermann C. Regulation of the expression of the inducible isoform of nitric oxide synthase. Adv Pharmacol 1995;34:113-54.
13. Southan GJ, Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51:383-394.
14. G-methyl-arginine. Biochem Biophys Res Commun 1990;170:96-103.
15. Feldmann PL, Griffith OW, Honh H, Stuehr D. Irreversible inactivation of macrophage and brain nitric oxide synthase by L-NG-methyl arginine requires NADPH-dependent hydroxylation. J Med Chem 1993;36:491-496.
16. Thiemermann C, Ruetten H, Wu CC, Vane JR. The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995;116:2845-2851.
17. Millar CGM, Thiemermann C. Intrarenal hemodynamics and renal dysfunction in endotoxemia: Effects of nitric oxide synthase inhibition. Br J Pharmacol 1997; In press.
18. Shultz PJ, Raij L. Endogenously synthetized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest 1992;90:1718-25.
19. Rees DD, Monkhouse JE, Deakin AM, Cambride D, Moncada S. The role of nitric oxide in a conscious mouse model of endotoxin shock. Br J Pharmacol 1995;114:123P.
20. Meyer J, Traber LD, Nelson S, et al. Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 1992;73:324-328.
21. Meyer J, Lentz CW, Stothert JC, Traber LD, Herndon DN, Traber DL. Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit Care Med 1994;22: 306-312.
22. Strohmeier W, Werner ER, Redl H, Wachter H, Schlag G. Plasma nitrate and pteridine levels in experimental bacteremia in baboons. Pteridines 1995;6:8-11.
23. Corbett JA, Tilton RG, Chang, K, et al. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992;41:552-558.
24. Misko TP, Moore WM, Kasten TP, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233:119-125.
25. Griffith MJ, Messent M, MacAllister RJ, Evans TW. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993;110:963-8.
26. G-nitro-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 1994;199:147-54.
27. Wu CC, Chen SJ, Szabo C, Thiemermann C, Vane JR. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 1995;114:1666-1672.
28. Wolff DJ, Lubeskie, A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys 1995;316:290-301.
29. Ruetten H, Southan GJ, Abate A, Thiemermann C. Attenuation of the multiple organ dysfunction caused by endotoxin by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 1996;118:261-270.
30. Seo HG, Fujiwara N, Kaneto H, Asashi M, Fujii J, Taniguchi N. Effect of the nitric oxide synthase inhibitor, S-ethyl-isothiourea, on cultured cells and cardiovascular functions of normal and lipopolysaccharide-treated rabbits. J Biochem 1996;119:553-8.
31. Muller CM, Scierka A, Stiller RL, et al. Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. Anesthesiology 1996;84:1435-42.
32. Ou J, Molina L, Kim YM, Billiar TR. Excessive NO production does not account for the inhibition of hepatic gluconeo-genesis in endotoxemia. Am J Physiol 1996;271:621-8.
33. Klabunde RE, Coston AF. Nitric oxide synthase inhibition does not prevent cardiac depression in endotoxic shock. Shock 1995;3:73-8.
34. Sorrells DL, Friend C, Koltuksuk U, et al. Inhibition of nitric oxide with aminoguanidine reduces bacterial translocation after endotoxin challenge in vivo. Arch Surg 1996;131:1155-63.
35. Boje KM. Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis. Brain Res 1996;720:75-83.
36. Arkovitz MS, Wispe JR, Garcia VF, Szabo C. Selective inhibition of the inducible isoform of nitric oxide synthase prevents pulmonary transvascular flux during acute endotoxemia. J Pediatr Surg 1996;31:1009-15.
37. Bieganski T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht CD, Feussner KD. Distribution and properties of human diamine oxidase and its relevance for the histamine catabolism. Biochem Biophys Acta 1983;756:196-203.
38. Seiler N, Bolkenius FN, Knodgen B. The influence of catabolic reactions on polyamine excretion. Biochem J 1985;225:219-226.
39. Ou P, Wolff SP. Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 1993;46:1139-44.
40. Picard S, Parthasarathy S, Fruebis J, Witzum JL. Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 1992;89:6876-80.
41. Ruetten H, Thiemermann, C. Prevention of the expression of inducible nitric oxide synthase by aminoguanidine or aminoethylisothiourea in macrophages and in the rat. Biochem Biophys Res Commun 1996;225:525-530.
42. Garvey PE, Oplinger JA, Tanoury GJ, et al. Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J Biol Chem 1994;269: 26669-76.
43. Szabo C, Southan G, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methyl-isothiourea sulfate, a novel, potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 1994;91:12472-76.
44. Southan G, Szabo C, Thiemermann C. Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 1995;114:510-16.
45. Southan GJ, Zingarelli B, O'Conner M, Salzman AL, Szabo C. Spontaneous rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform. Br J Pharmacol 1996;117:619-32.
46. Martinez MC, Muller B, Stoclet JC, Andriantsitohaina R. Alteration by lipopolysaccharide of the relationship between intracellular calcium levels and contraction in rat mesenteric artery. Br J Pharmacol 1996;118:1218-22.
47. Saetre T, Gundersen Y, Thiemermann C, Lilleansen P, Aasen AO. Aminoethyl-isothiourea, a selective inhibitor of inducible nitric oxide synthase activity, improves liver circulation and oxygen metabolism in a porcine model of endotoxaemia. Shock 1997; in press.
48. Muraki T, Fujii E, Okada M, Horikawa H, Irie K, Ohba K. Effect of S-ethyl-isothiourea, a putative inhibitor of inducible nitric oxide synthase, on mouse skin vascular permeability. Jpn J Pharmacol 1996;70:269-71.
49. Vromen A, Szabo C, Southan GJ, Salzman AL. Effects of S-isopropyl isothiourea, a potent inhibitor of nitric oxide synthase, in severe hemorrhagic shock. J Appl Physiol 1996;81:707-15.
50. Southan GJ, Szabo C, O'Conner MP, Salzman AC, Thiemermann C. Amidines are potent inhibitors of nitric oxide synthases: Preferential inhibition of the inducible isoform. Eur J Pharmacol 1995;291:311-318.
51. Garvey EP, Oplinger JA, Furfine ES, et al. 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J Biol Chem 1997;272:4959-63.
52. Wei X, Charles IG, Smith, A et al. Altered immune responses in mice lacking inducible nitric oxide synthase. 1995;375:408-411.
53. MacMicking JD, Nathan C, Hom G, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;82:641-650.
54. Laubach VE, Sheseley EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 1995;92:10668-92.